Man Group plc Takes Position in Kymera Therapeutics, Inc. $KYMR

Man Group plc purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the second quarter, Holdings Channel.com reports. The firm purchased 19,085 shares of the company’s stock, valued at approximately $2,188,000.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. Baker BROS. Advisors LP boosted its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. raised its stake in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, BlackRock Inc. purchased a new position in Kymera Therapeutics in the 2nd quarter worth approximately $635,067,000.

Analyst Ratings Changes

A number of brokerages have issued reports on KYMR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. TD Cowen raised shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Canaccord Genuity Group boosted their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $128.70.

Insider Buying and Selling

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $79,321,592. This trade represents a 6.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,587,629 shares of company stock valued at $386,183,782 in the last three months. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $119.05 on Wednesday. Kymera Therapeutics, Inc. has a 1-year low of $39.84 and a 1-year high of $130.05. The business has a 50 day simple moving average of $113.58 and a two-hundred day simple moving average of $94.25. The stock has a market capitalization of $9.90 billion, a PE ratio of -36.74 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) EPS. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.